Nothing Special   »   [go: up one dir, main page]
Jump to content

Ibopamine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 20:07, 21 January 2014 (Updating {{drugbox}} (changes to verified and watched fields - added verified revid - updated 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'CAS_number_Ref', 'Verifiedfields', 'Watchedfields', 'verifiedrevid') per [[WP:CHEMVALID|Chem/Drugbox v...). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Ibopamine
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • 5-[2-(methylamino)ethyl]-2-[(2-methylpropanoyl)oxy]phenyl 2-methylpropanoate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.060.189 Edit this at Wikidata
Chemical and physical data
FormulaC17H25NO4
Molar mass307.385 g/mol g·mol−1
3D model (JSmol)
  • O=C(Oc1cc(ccc1OC(=O)C(C)C)CCNC)C(C)C
  • InChI=1S/C17H25NO4/c1-11(2)16(19)21-14-7-6-13(8-9-18-5)10-15(14)22-17(20)12(3)4/h6-7,10-12,18H,8-9H2,1-5H3 ☒N
  • Key:WDKXLLJDNUBYCY-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Ibopamine is a sympathomimetic drug, designed as a prodrug of epinine, used in ophthalmology.[1] It induces mydriasis.[2] It also has been investigated for use in the treatment of congestive heart failure.[3]

It acts on D1[4][5] and α receptors as an agonist.[6]

Ibopamine was first prepared by Casagrande and co-workers.[7]

See also

References

  1. ^ Magacho L, Costa ML, Dessimoni A, de Avila MP (2006). "Comparison between the 1% and 2% ibopamine provocative test in primary open-angle glaucoma patients: sensitivity, specificity and tolerability". Arq Bras Oftalmol. 69 (5): 695–9. doi:10.1590/S0004-27492006000500015. PMID 17187138.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  2. ^ Marchini G, Babighian S, Tosi R, Perfetti S, Bonomi L (June 2001). "Effects of 2% ibopamine on pupil, refraction, anterior segment anatomy and intraocular pressure". J Ocul Pharmacol Ther. 17 (3): 215–23. doi:10.1089/108076801750295254. PMID 11436942.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. ^ van Veldhuisen DJ, Man in 't Veld AJ, Dunselman PH; et al. (November 1993). "Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT)". J. Am. Coll. Cardiol. 22 (6): 1564–73. doi:10.1016/0735-1097(93)90579-P. PMID 7901256. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  4. ^ Metra M, Missale C, Spano PF, Cas LD (May 1995). "Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine". J. Cardiovasc. Pharmacol. 25 (5): 732–40. doi:10.1097/00005344-199505000-00008. PMID 7630152.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  5. ^ Lieverse AG, Girbes AR, Van Veldhuisen DJ; et al. (July 1995). "The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure". Eur. Heart J. 16 (7): 937–42. PMID 7498209. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  6. ^ "IngentaConnect Ibopamine Stimulates -Adrenergic Receptors and D1 Dopaminergic Re..."
  7. ^ C. Casagrande, F. Santangelo, C. Saini, F. Doggi, F. Gerli and O. Cerri (1986). "Synthesis and chemical properties of ibopamine and of related esters of N-substituted dopamines-synthesis of ibopamine metabolites." Arzneimittelforschung 36 291-303.


Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Ibopamine&oldid=591761896"